drugset / Trial / NCT06355232
Covid-19 and Influenza Oral Vaccine Study
Phase 1
Recruiting
100 enrolled
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute · collab
RandomizedCrossoverTriple-blindPrevention
Summary
The purpose of the current study is to assess the effectiveness of protein-based COVID-19 or influenza vaccines when given individually or together via oral/ sublingual mucosal route instead of intramuscular delivery. The comparator will be a seasonal influenza vaccine which will also be administered with Advax-CpG adjuvant via the oral route. This study will use a cross-over design and everyone in the study will over a space of about 4 months receive both the COVID-19 and influenza vaccines.
Timeline
- Start
- 2024-05-01
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Influenza Virus Vaccine | Vaccine | — | Other |
| Subject | Spikogen | Vaccine | — | Other |